Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Genetic evolution of Waldenström macroglobulinemia across disease stages

Blood (2025) 146 (Supplement 1): 3540.

https://doi.org/10.1182/blood-2025-3540

Published: 2025

Journal Articles

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Blood (2025) 146 (Supplement 1): 2999.

https://doi.org/10.1182/blood-2025-2999

Published: 2025

Journal Articles

Evolving insights and changes in survival of erdheim-chester disease over time

Blood (2025) 146 (Supplement 1): 2990.

https://doi.org/10.1182/blood-2025-2990

Published: 2025

Journal Articles

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Ayo Falade, Yu Tao, Olisaemeka Ogbue, Oluwatayo Adeoye, Ayodeji Johnson, Arushi Khurana, Jithma Abeykoon, Urshila Durani, Mazie Tsang, Allison Rosenthal, Talal Hilal, Javier Munoz, Patrick Johnston, Han Tun, Grzegorz Nowakowski, James Cerhan, Richard Godby, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2025-4494

Published: 2025

Journal Articles

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 473.

https://doi.org/10.1182/blood-2025-473

Published: 2025

Journal Articles

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Julia Wang, Steven Hwang, Urshila Durani, Gita Thanarajasingam, Arushi Khurana, Jonas Paludo, Yucai Wang, Grzegorz Nowakowski, Thomas Habermann, Thomas Witzig, Stephen Ansell, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 5399.

https://doi.org/10.1182/blood-2025-5399

Published: 2025

Journal Articles

Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma

Giuseppe Maiocco, Yoshito Nishimura, Guneet Janda, Yiqun Han, Urshila Durani, Grzegorz Nowakowski, Jonas Paludo, Stephen Ansell, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 5395.

https://doi.org/10.1182/blood-2025-5395

Published: 2025

Journal Articles

30 years of classical hematology drugs in the US: Approvals, costs, and sales

Lewis Go, Lucas Go, Michelle Elliott, Richard Godby, Chelsee Jensen, Leslie Padrnos, Rajiv Pruthi, Candido Rivera, Rachelle Rouse, Surbhi Shah, Marwan Shaikh, Mustaqeem Siddiqui, Meera Sridharan, Alexandra Wolanskyj-Spinner, Ewa Wysokinska, Ronald Go, Jithma Abeykoon

Blood (2025) 146 (Supplement 1): 2604.

https://doi.org/10.1182/blood-2025-2604

Published: 2025

Journal Articles

Mutational landscape of adult xanthogranuloma

Blood (2025) 146 (Supplement 1): 7339.

https://doi.org/10.1182/blood-2025-7339

Published: 2025

Journal Articles

Volume and nature of classical hematology outpatient consults within a national cancer institute-designated comprehensive cancer center

Emily Wolf, Michelle Neitzke, Jithma Abeykoon, Michelle Elliott, Brooke Gentzler, Richard Godby, Rajiv Pruthi, Rachelle Rouse, Mustaqeem Siddiqui, Meera Sridharan, Leslie Padrnos, Surbhi Shah, Jordan Davis, Amanda Tippitt, Candido Rivera, Marwan Shaikh, Alexandra Wolanskyj-Spinner, Ewa Wysokinska, Ronald Go

Blood (2025) 146 (Supplement 1): 8208.

https://doi.org/10.1182/blood-2025-8208

Published: 2025

Journal Articles

The molecular landscape of patients with malignant histiocytosis

Alanis Rodriguez-Rosario, Jithma Abeykoon, N. Nora Bennani, Karen Rech, Mithun Shah, Aishwarya Ravindran, Aldo Acosta Medina, Gordon Ruan, Dongni Yi, Saurabh Zanwar, Gaurav Goyal, Ronald Go

Blood (2025) 146 (Supplement 1): 7335.

https://doi.org/10.1182/blood-2025-7335

Published: 2025

Journal Articles

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

XI Yang, Haadi Ali, Dana Bossert, Carla Isabel Borre, Brinda H Shukla, Jacquelyn Fitzgerald, Mikaela McDonough, Corbin Wright, Fnu Amisha, Samuel Reynolds, Eric Jacobsen, Eli Diamond, Gaurav Goyal, Jithma Abeykoon, Ronald Go, Asra Ahmed

Blood (2025) 146 (Supplement 1): 726.

https://doi.org/10.1182/blood-2025-726

Published: 2025

Journal Articles

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Blood (2025) 146 (Supplement 1): 6760.

https://doi.org/10.1182/blood-2025-6760

Published: 2025

Journal Articles

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

Xiaosheng Wu, Mary Stenson, Jithma Abeykoon, Kevin Nowakowski, Lianwen Zhang, Joshua Lawson, Linda Wellik, Ying Li, Jordan Krull, Kerstin Wenzl, Anne J. Novak, Stephen M. Ansell, Gail A. Bishop, Daniel D. Billadeau, Kah Whye Peng, Francis Giles, Daniel M. Schmitt, Thomas E. Witzig

Blood (2019) 134 (4): 363–373.

https://doi.org/10.1182/blood.2018874560

Published: 2019

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genetic evolution of Waldenström macroglobulinemia across disease stages

Efficacy of frontline fixed duration chemotherapy in MAPK-pathway altered adult langerhans cell histiocytosis: A multi-institutional international retrospective study

Evolving insights and changes in survival of erdheim-chester disease over time

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

A national cancer database study of survival trends in patients with classical Hodgkin lymphoma: Improved survival in the novel agent era

Real-world outcomes of immune checkpoint inhibitor rechallenge in patients with classical Hodgkin lymphoma

30 years of classical hematology drugs in the US: Approvals, costs, and sales

Mutational landscape of adult xanthogranuloma

Volume and nature of classical hematology outpatient consults within a national cancer institute-designated comprehensive cancer center

The molecular landscape of patients with malignant histiocytosis

Discontinuation of targeted therapy in histiocytic neoplasms with durable response: A multicenter retrospective study

KRAS mutations in histiocytic neoplasms: Mutation spectrum and response to MEK inhibition

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only